Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Neuroendocrine carcinoma
Stage/Subtype:  thyroid gland medullary carcinoma
Trial Type:  Treatment
Trial Status:  Active
Results 1-18 of 18 for your search:
Start Over
Total Thyroidectomy With Harmonic Scalpel®
Phase: Phase IV
Type: Health services research, Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: CP005, NCT00385983
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230B2412, NCT01794793
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-401, NCT01896479
Radiolabeled Molecules for Medullary Thyroid Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: Lu177-med, NCT01915485
Randomized Phase III of PRRT Versus Interferon
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: IJBMNCASTOR, 2012-005545-20, NCT01860742
DOTA-TOC in Metastasized Neuroendocrine Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MAW002, NCT00978211
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 78,256, NCT01237457
A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB00041909, WCI1777-09, NCT01270321
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 2010-023128-26, NCT01625520
Nintedanib(BIBF1120) in Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-1209, 2012-004295-19, NCT01788982
Ponatinib for Advanced Medullary Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130108, 13-C-0108, NCT01838642
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00831, ALLIANCE A021202, CALGB-A021202, A021202, U10CA180821, U10CA031946, NCT01841736
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: UC-0105/1303, 2013-000885-13, NCT02034981
Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 410-30610-258, NCT02084732
A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: GI-6207-02, NCT01856920
Phase Ib Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2014-012-00CH1, NCT02267967
Tumor Metabolism of Head and Neck Cancer in Patients Who Underwent Radiation Therapy Measured With F-18-FDG-PET
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: HNO-FDG-FU, NCT00180245
Best Therapy for Patients With Neuroendocrine Tumors
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: ZBB-NET-1, NCT00815620
Start Over